EP Patent

EP4066849A1 — Daptomycin formulations and uses thereof

Assigned to Hospira Australia Pty Ltd · Expires 2022-10-05 · 4y expired

What this patent protects

Lyophilised daptomycin formulations having improved reconstitution times are provided. The lyophilised daptomycin formulations include citric acid. The lyophilised daptomycin formulations are useful in methods of treating bacterial infections.

USPTO Abstract

Lyophilised daptomycin formulations having improved reconstitution times are provided. The lyophilised daptomycin formulations include citric acid. The lyophilised daptomycin formulations are useful in methods of treating bacterial infections.

Drugs covered by this patent

Patent Metadata

Patent number
EP4066849A1
Jurisdiction
EP
Classification
—
Expires
2022-10-05
Drug substance claim
No
Drug product claim
No
Assignee
Hospira Australia Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.